Literature DB >> 2695329

Effects of cilofungin (LY121019) on carbohydrate and sterol composition of Candida albicans.

M Pfaller1, J Riley, T Koerner.   

Abstract

Cilofungin (LY 121019) is a novel analogue of echinocandin B with potent activity against Candida albicans. The effects of cilofungin on the sterol and cell wall carbohydrate composition of Candida albicans were investigated. Exposure of Candida albicans to cilofungin resulted in a 55-60% decrease in ergosterol and a 4-13% decrease in lanosterol content relative to controls. Carbohydrate analysis revealed a 72-79% decrease in glucan content and no significant decrease in mannan or chitin content relative to controls. These studies suggest that cilofungin specifically inhibits glucan synthesis in Candida albicans and thus may be less toxic to mammalian cells. The effects of cilofungin on sterol composition may be non-specific and will require additional investigation.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2695329     DOI： 10.1007/BF01975172

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


  8 in total

1.  Studies on yeast metabolism. I. Fractionation and microdetermination of cell carbohydrates.

Authors:  W E TREVELYAN; J S HARRISON
Journal:  Biochem J       Date:  1952-01       Impact factor: 3.857

2.  Anti-Candida activity and toxicology of LY121019, a novel semisynthetic polypeptide antifungal antibiotic.

Authors:  R S Gordee; D J Zeckner; L C Howard; W E Alborn; M Debono
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

3.  Antibiotic tetaine--a selective inhibitor of chitin and mannoprotein biosynthesis in Candida albicans.

Authors:  S Milewski; H Chmara; E Borowski
Journal:  Arch Microbiol       Date:  1986-08       Impact factor: 2.552

4.  The effects of ergosterol and alcohols on germ-tube formation and chitin synthase in Candida albicans.

Authors:  Y Y Chiew; P A Sullivan; M G Shepherd
Journal:  Can J Biochem       Date:  1982-01

5.  On the mode of action of a new antifungal antibiotic, aculeacin A: inhibition of cell wall synthesis in Saccharomyces cerevisiae.

Authors:  J Mizoguchi; T Saito; K Mizuno; K Hayano
Journal:  J Antibiot (Tokyo)       Date:  1977-04       Impact factor: 2.649

6.  Chitin synthesis and localization in cell division cycle mutants of Saccharomyces cerevisiae.

Authors:  R L Roberts; B Bowers; M L Slater; E Cabib
Journal:  Mol Cell Biol       Date:  1983-05       Impact factor: 4.272

7.  Cilofungin (LY121019) inhibits Candida albicans (1-3)-beta-D-glucan synthase activity.

Authors:  C S Taft; T Stark; C P Selitrennikoff
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

Review 8.  Biochemical targets for antifungal azole derivatives: hypothesis on the mode of action.

Authors:  H Vanden Bossche
Journal:  Curr Top Med Mycol       Date:  1985
  8 in total
  14 in total

Review 1.  Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance.

Authors:  M A Ghannoum; L B Rice
Journal:  Clin Microbiol Rev       Date:  1999-10       Impact factor: 26.132

2.  Canadian clinical practice guidelines for invasive candidiasis in adults.

Authors:  Eric J Bow; Gerald Evans; Jeff Fuller; Michel Laverdière; Coleman Rotstein; Robert Rennie; Stephen D Shafran; Don Sheppard; Sylvie Carle; Peter Phillips; Donald C Vinh
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

Review 3.  Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.

Authors:  Leah E Cowen; William J Steinbach
Journal:  Eukaryot Cell       Date:  2008-03-28

4.  In vitro activity of the new semi-synthetic polypeptide cilofungin (LY121019) against Aspergillus and Candida species.

Authors:  A Huang; F Edwards; E M Bernard; D Armstrong; H J Schmitt
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-09       Impact factor: 3.267

Review 5.  Compounds active against cell walls of medically important fungi.

Authors:  R F Hector
Journal:  Clin Microbiol Rev       Date:  1993-01       Impact factor: 26.132

6.  Caspofungin dose escalation for invasive candidiasis due to resistant Candida albicans.

Authors:  Nathan P Wiederhold; Laura K Najvar; Rosie A Bocanegra; William R Kirkpatrick; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2011-04-18       Impact factor: 5.191

7.  Comparative efficacies of cilofungin (Ly121019) and amphotericin B against disseminated Candida albicans infection in normal and granulocytopenic mice.

Authors:  N Khardori; H Nguyen; L C Stephens; L Kalvakuntla; B Rosenbaum; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

8.  In vitro comparison of cilofungin alone and in combination with other antifungal agents against clinical isolates of Candida species.

Authors:  K R Smith; K M Lank; W E Dismukes; C G Cobbs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-07       Impact factor: 3.267

Review 9.  Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications.

Authors:  C A Lyman; T J Walsh
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

10.  Effects of fluconazole on the sterol and carbohydrate composition of four species of Candida.

Authors:  M Pfaller; J Riley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-02       Impact factor: 3.267
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.